InFlectis BioScience
Entity

  • InFlectis BioScience

    Created in 2013
    Inactive since August 2018
  • BETA

    Probably non active (C)
    Several signals show that this company is not active anymore

  • Social networks

    1,035

  • Activities

    biotech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    21 Rue La Noue Bras de Fer, 44200 Nantes, France

    Nantes

    France

  • Employees

    Scale: 2-10

    Estimated: 9

  • SIREN

    795009604

  • Engaged corporates

    2
    2 0

  • Added in Motherbase

    6 years, 3 months ago
Description
  • Value proposition

    Developpment of small molecules to prolong the protective effect of the Integrated Stress Response

    InFlectis BioScience is a private clinical-stage company aiming to target and modulate interactions between proteins involved in key human pathophysiological processes. The company is developing IFB-088 (INN: icerguastat), which specifically targets the Integrated Stress Response (ISR).
    Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of diseases affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation. IFB-088 is currently in phase 2 trial to treat ALS.

    Company History
    InFlectis BioScience has been founded by Dr. Philippe GUEDAT on August 30, 2013. He discovered IFB-088 (INN: icerguastat) in collaboration with an academic team at the MRC Laboratory of Molecular Biology (LMB) in Cambridge UK.

    Dr Philippe GUEDAT was awarded at the 2013 and 2014 National Competition of Business Startups using Innovative Technologies by the Ministry of Research in France.

    - 2013: Prize of Emergence section: €50k
    https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-laureats-concours-national-i-lab/table/?refine.annee_de_concours=2013&refine.region=Pays+de+la+Loire

    - 2014: Prize of Creation-Development section: €300k
    https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-laureats-concours-national-i-lab/table/?refine.region=Pays+de+la+Loire&refine.annee_de_concours=2014


    Protein misfolding diseases, Orphan diseases, Charcot-Marie-Tooth, Amyotrophic Lateral Scelrosis, Neuromuscular diseases, Inflammatory diseases, ALS, CMT, MS, Multiple sclerosis, Integrated Stress Response, ISR modulators, Clinical Stage, and IFB-088

  • Original language

    Developpment of small molecules to prolong the protective effect of the Integrated Stress Response

    InFlectis BioScience is a private clinical-stage company aiming to target and modulate interactions between proteins involved in key human pathophysiological processes. The company is developing IFB-088 (INN: icerguastat), which specifically targets the Integrated Stress Response (ISR).
    Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of diseases affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation. IFB-088 is currently in phase 2 trial to treat ALS.

    Company History
    InFlectis BioScience has been founded by Dr. Philippe GUEDAT on August 30, 2013. He discovered IFB-088 (INN: icerguastat) in collaboration with an academic team at the MRC Laboratory of Molecular Biology (LMB) in Cambridge UK.

    Dr Philippe GUEDAT was awarded at the 2013 and 2014 National Competition of Business Startups using Innovative Technologies by the Ministry of Research in France.

    - 2013: Prize of Emergence section: €50k
    https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-laureats-concours-national-i-lab/table/?refine.annee_de_concours=2013&refine.region=Pays+de+la+Loire

    - 2014: Prize of Creation-Development section: €300k
    https://data.enseignementsup-recherche.gouv.fr/explore/dataset/fr-esr-laureats-concours-national-i-lab/table/?refine.region=Pays+de+la+Loire&refine.annee_de_concours=2014

Corporate interactions BETA
Corporate TypeTweets Articles
France Biotech
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research
France Biotech
Startup accelerator & VC, Biotechnology, Biotechnology Research 		Other

18 Jan 2024


Atlanpole Biotherapies
Atlanpole Biotherapies
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Atlanpole Biotherapies
Public business cluster, Biotechnology, French Cluster, Biotechnology Research 		Other

7 Jun 2024


Similar entities
Last news
Show all articles
Social network dynamics